Improving Outcomes for Limited Stage Small Cell Lung Cancer Patients in Scotland with Concomitant Chemoradiation

Clinical Oncology

Volumn 19, Issue 3, 2007, Pages 188-193

  Law, A B ^a   Erridge, S C ^a   MacKean, M J ^a   Kerr, G R ^a   Ironside, J A D ^a   Little, F A ^a   Price, A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy; concomitant radiotherapy; small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MEDICAL RECORD; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SCOTLAND;

EID: 33847071117     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.01.112     Document Type: Article

References (23)

1. Laskin J.J., Erridge S.C., Coldman A.J., et al. Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia. [see comment]. Lung Cancer 43 1 (2004) 7-16
2. Mahmud S.M., Reilly M., and Comber H. Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer 41 1 (2003) 57-64
3. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. [see comment]. N Engl J Med 327 23 (1992) 1618-1624
4. Warde P., and Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. [see comment]. J Clin Oncol 10 6 (1992) 890-895
5. Murray N., Coy P., Pater J., et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11 2 (1993) 336-344
6. Erridge S.C., and Murray N. Thoracic radiotherapy for limited-stage small cell lung cancer: issues of timing, volumes, dose, and fractionation. Semin Oncol 30 1 (2003) 26-37
7. Bonner J.A., Sloan J.A., Shanahan T.G., et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17 (1999) 2681-2691
8. Takada M., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. [see comment]. J Clin Oncol 20 14 (2002) 3054-3060
9. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. [see comment]. N Engl J Med 340 4 (1999) 265-271
10. Gregor A., Thomson C.S., Brewster D.H., et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 56 3 (2001) 212-217
11. Lester J., Hudson E., Flubacher M., et al. Small cell lung cancer treated in southeast Wales. Clin Oncol (R Coll Radiol) 18 5 (2006) 378-382
12. Spiro S., James L., Rudd R., et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group. J Clin Oncol 24 (2006) 3823-3830
13. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24 7 (2006) 1057-1063
14. Newaishy G., and Kelly C. An audit of survival in small cell lung cancer. Clin Oncol (R Coll Radiol) 4 6 (1992) 36207
15. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 9 (1999) 2692-2699
16. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15 3 (1997) 893-900
17. Fried D.B., Morris D.E., Poole C., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 23 (2004) 4837-4845 2005;23(1):248
18. Peters L., and Withers H. Applying radiobiological principles to combined modality treatment of head and neck cancer - the time factor. Int J Radiat Oncol Biol Phys 39 4 (1997) 831-836
19. Gaspar L., Gay E., Crawford J., Putnam J., Herbst R., and Bonner J. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 6 6 (2005) 355-360
20. Cartman M.L., Hatfield A.C., Muers M.F., et al. Lung cancer: district active treatment rates affect survival. J Epidemiol Commun Health 56 6 (2002) 424-429
21. Erridge S.C., Thomson C.S., Davidson J., Jones R.D., Price A., and Scottish Cancer Trials Lung Group and Scottish Cancer Therapy. Factors influencing the use of thoracic radiotherapy in lung cancer - an analysis of the 1995 Scottish lung cancer audit. [see comment]. Clin Oncol (R Coll Radiol) 14 3 (2002) 219-227
22. Jack R.H., Gulliford M.C., Ferguson J., and Moller H. Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services?. Br J Cancer 88 7 (2003) 1025-1031 2004;91(10):1852
23. Baas P., Belderbos J.S., Senan S., et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer 94 5 (2006) 625-630